620 related articles for article (PubMed ID: 17470526)
1. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
2. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
[TBL] [Abstract][Full Text] [Related]
3. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
5. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
9. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
[TBL] [Abstract][Full Text] [Related]
10. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
12. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
Westerhout J; Smeets J; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
14. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
Elmeliegy MA; Carcaboso AM; Tagen M; Bai F; Stewart CF
Clin Cancer Res; 2011 Jan; 17(1):89-99. PubMed ID: 21088257
[TBL] [Abstract][Full Text] [Related]
15. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
Doran A; Obach RS; Smith BJ; Hosea NA; Becker S; Callegari E; Chen C; Chen X; Choo E; Cianfrogna J; Cox LM; Gibbs JP; Gibbs MA; Hatch H; Hop CE; Kasman IN; Laperle J; Liu J; Liu X; Logman M; Maclin D; Nedza FM; Nelson F; Olson E; Rahematpura S; Raunig D; Rogers S; Schmidt K; Spracklin DK; Szewc M; Troutman M; Tseng E; Tu M; Van Deusen JW; Venkatakrishnan K; Walens G; Wang EQ; Wong D; Yasgar AS; Zhang C
Drug Metab Dispos; 2005 Jan; 33(1):165-74. PubMed ID: 15502009
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
Chen C; Hanson E; Watson JW; Lee JS
Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
[TBL] [Abstract][Full Text] [Related]
17. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.
Rao VV; Dahlheimer JL; Bardgett ME; Snyder AZ; Finch RA; Sartorelli AC; Piwnica-Worms D
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3900-5. PubMed ID: 10097135
[TBL] [Abstract][Full Text] [Related]
18. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.
Zhu HJ; Wang JS; DeVane CL; Williard RL; Donovan JL; Middaugh LD; Gibson BB; Patrick KS; Markowitz JS
Drug Metab Dispos; 2006 Jul; 34(7):1116-21. PubMed ID: 16621932
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Oberoi RK; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
